selumetinib   Click here for help

GtoPdb Ligand ID: 5665

Synonyms: ARRY-142886 | ARRY-886 | AZD6244 | Koselugo® | NSC 741O78
Approved drug PDB Ligand
selumetinib is an approved drug (FDA (2020))
Compound class: Synthetic organic
Comment: Selumetinib is a selective, orally bioavailable MEK1/2 inhibitor [5].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

selumetinib is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 4
Hydrogen bond donors 3
Rotatable bonds 7
Topological polar surface area 88.41
Molecular weight 456
XLogP 3.7
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES OCCONC(=O)c1cc2n(C)cnc2c(c1Nc1ccc(cc1Cl)Br)F
Isomeric SMILES OCCONC(=O)c1cc2n(C)cnc2c(c1Nc1ccc(cc1Cl)Br)F
InChI InChI=1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)
InChI Key CYOHGALHFOKKQC-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Selumetinib (administered clinically as the hydrogen sulfate) was investigated for the treatment of various types of cancer, such as non-small cell lung cancer (NSCLC) and AIDS-related Kaposi's sarcoma. Click here to view ClinicalTrials.gov's list of registered selumetinib trials.
In April 2015, the US FDA granted selumetinib orphan drug status as a treatment for uveal melanoma. Since July 2018 selumetinib has held EMA orphan designation for the treatment of neurofibromatosis type 1 (NF1).
The first FDA approval of selumetinib was granted in April 2020, as a therapy for pediatric patients (≥2 years of age), who have symptomatic NF1-associated, inoperable plexiform neurofibromas (PN) [3].
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Selumetinib inhibits the MAPK kinases, MEK1 and MEK2 [6]. These kinases act in the MAPK/ERK pathway, downstream of BRAF and KRAS, two additional kinases which have been shown to carry activating mutations in some cancers [1]. Inhibition of MEK1/2 reduces abberant signalling in the growth factor-responsive MAPK/ERK signalling pathway in such cancer cells, and thereby reduces tumour growth.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01362803 AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors Phase 1/Phase 2 Interventional National Institutes of Health Clinical Center (CC) Selumetinib was approved as the first oral monotherapy for pediatric patients with NF1-related plexiform neurofibromas. Regulatory approval was based on results from the SPRINT (NCT01362803) clinical trial which showed that selumetinib induced durable tumour shrinkage and clinical benefit in these patients. 4